# First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

> **NCT01215344** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** VELCADE
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** DVT prophylaxis
- **DRUG:** Bisphosphonates
- **DRUG:** Liposomal doxorubicin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01215344
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-11
- **Final completion:** 2018-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215344, "First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01215344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*